IFx-2.0
Gene therapy / editing
Evidence outlook · registrational
Merkel Cell Carcinoma: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2027-03-31.
Company guidance: data expected 1H2027 (TuHURA Biosciences, 13 Nov 2026). “1H2027: Expect preliminary results from front-line study IFX-2.0 with Keytruda® when administered by CT or ultrasound-guided techniques to metastatic deep seated MCC” Source ↗
Company guidance: topline data expected second half of 2027 (TuHURA Biosciences, 13 Nov 2026). “We anticipate topline results from the Phase 3 accelerated approval trial of IFx-2.0 in the second half of 2027.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06947928 NCT06947928 · Merkel Cell Carcinoma Registry: NCT06947928 | 2/3 | Objective response rate (ORR) (12 weeks post-treatment initiation and confirmed on a second response assessment at least 28 days after the initial response assessment) 2027-03-31 | In progress: results expected 31 Mar 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2/3 (1)
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Merkel Cell Carcinoma: Phase 2/3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| IFx-2.0: this drug | Phase 2/3 | Gene therapy / editing | Innate immune activation (intralesional plasmid DNA) | not yet graded | No reviewed efficacy summary in this indication | |
| Avelumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Weak signal | NCT03783078: Objective Response Rate (ORR) (Up to ~34 months): Pembrolizumab 200 mg 49.1 Percentage of participants (95% CI 35.4 to 62.9) NCT02267603: Objective Response Rate (ORR) Defined as the Proportion of Patients Who Have Achieved Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Up to 3 years): Treatment (Pembrolizumab) — Number participants with partial response (PR): 16 Participants; Number participants with complete response (CR): 12 Participants; Combined total participants with either PR or CR: 28 Participants | |
| Retifanlimab | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow IFx-2.0 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.